On March 19, the FDA approved atezolizumab (Tecentriq®, Genentech) in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Read the Roche press release here.
Read the FDA press release here.
Download the Tecentriq ES-SCLC Day 1 Letter here.
Posted 3/19/2019
Recognizing the critical role advanced practice providers and allied health professionals play in the care continuum, the American Oncology Network provides infrastructure, leadership, and professional growth opportunities to empower these members of the cancer care team to practice at the top of their license.
